US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ASTRAZENECA PLC ADRhedged

53.28

0.0000

Volume:- -

Turnover:- -

Market Cap:1.60M

PE:- -

High:53.28

Open:53.28

Low:53.28

Close:53.28

52wk High:56.90

52wk Low:44.36

Shares:30.00K

Float Shares:10.00K

Volume Ratio:2.68

T/O Rate:- -

Dividend:0.58

Dividend Rate:1.08%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

AstraZeneca PLC Stock Rises Wednesday, Outperforms Market

Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements

AstraZeneca completes global license agreement for Zegfrovy in lung cancer

AstraZeneca Reports 'Meaningful Improvement' in Phase 3 Study of Lung Cancer Patients

MT Newswires Live

AstraZeneca Says Breast Cancer Combo Approved in EU; Completes Acquisition of License for Lung Cancer Treatment

MT Newswires Live

AstraZeneca PLC Stock Rises Monday, Outperforms Market

Hutchmed Says Lung Cancer Therapy Improves Progression-Free Survival in China Phase 3 Trial

MT Newswires Live

AstraZeneca PLC Stock Falls Friday, Underperforms Market

Jefferies sees neutral to negative read-through to Alnylam from AstraZeneca data

AstraZeneca Targets Pediatric Asthma Gains With New Glycopyrronium Trial

AstraZeneca Advances Off‑the‑Shelf CAR‑T Program in Tough‑to‑Treat Multiple Myeloma

Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements

Amgen, AstraZeneca report CROSSING trial met co-primary and secondary endpoints

AstraZeneca, Amgen Phase 3 Trial Shows Tezspire Eases Swallowing Difficulties for EoE Patients

MT Newswires Live

AstraZeneca's Tezspire Meets Esophagitis Late-Stage Trial Goals

AstraZeneca Slides Wednesday, Underperforms Market

AstraZeneca Deepens Its Type 2 Diabetes Pipeline With New Global Patient Mapping Study

AstraZeneca Climbs Tuesday, Outperforms Market

AstraZeneca (AZN) Receives a Sell from Deutsche Bank

Astrazeneca Prices $2.97 Billion Eurobond Offering

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/AZNH/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AZNH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AZNH\",,,,,undefined,":{"symbol":"AZNH","market":"US","secType":"STK","nameCN":"ASTRAZENECA PLC ADRhedged","latestPrice":53.2774,"timestamp":1788984000000,"preClose":53.2774,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":10000,"shares":30000,"eps":0,"marketStatus":"Halted","change":0,"latestTime":"09-10 07:57:20 EDT","open":53.2774,"high":53.2774,"low":53.2774,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789047000000},"marketStatusCode":1,"adr":0,"exchange":"NYSE","adjPreClose":53.2774,"dividendRate":0.010836,"bidAskSpread":0,"volumeRatio":2.6812474453400963},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AZNH\",,,,,undefined,":{"symbol":"AZNH","floatShares":10000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.6812474453400963,"shares":30000,"dividePrice":0.57729,"high":53.2774,"amplitude":0,"preClose":53.2774,"low":53.2774,"week52Low":44.36,"pbRate":"--","week52High":56.8955,"institutionHeld":0,"latestPrice":53.2774,"eps":0,"divideRate":0.010836,"volume":0,"delay":0,"ttmEps":0,"open":53.2774,"prevYearClose":54.226,"prevWeekClose":53.2774,"prevMonthClose":53.2774,"prevQuarterClose":53.2774,"fiveDayClose":53.2774,"twentyDayClose":53.2774,"sixtyDayClose":53.2774},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AZNH\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"AZNH","amount":0.57729,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"ASTRAZENECA PLC ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"},{"date":"2024-12-16","symbol":"AZNH","amount":2.71402,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-16","defaultRemindTime":1734359400000,"name":"ASTRAZENECA PLC ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-23","payableDate":"2024-12-16","currency":"USD","dateTimestamp":1734325200000,"payDate":"2024-12-23"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AZNH\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-16","recordDate":"2024-12-16","paymentDate":"2024-12-23","value":2.71402,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.57729,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AZNH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AZNH\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664484058","title":"AstraZeneca PLC Stock Rises Wednesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2664484058","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664484058?lang=en_us&edition=fundamental","pubTime":"2026-09-03 00:00","pubTimestamp":1788364800,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of AstraZeneca PLC advanced 0.3% to SEK1,560.50 Wednesday on what proved to be an overall poor trading session for the stock market, with the OMX Nordic 40 Index falling 0.3% to 2,678.58.The company closed SEK365.00 short of its 52-week high of SEK1,925.50, which the company achieved on April 10, 2026.Trading volume was 594,091, compared to the 50-day average trading volume of 556,904.Data source: Dow Jones Market Data, FactSet","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","LU2237443895.HKD","AZNH","LU2237443978.SGD","BK4568","LU0289739699.SGD","LU2237443382.USD","LU0432979614.USD","LU1267930573.SGD","LU2237443465.HKD","LU2462157665.USD","BK4007","BK4585","LU2468319806.SGD","LU0058720904.USD","LU1829250122.USD","LU0320765992.SGD","LU0708994859.HKD","LU0889565916.HKD","BK4588","LU2236285917.USD","IE00B3T34201.USD","LU2417539215.USD","LU0109394709.USD","LU0310800379.SGD","AZN","LU0029864427.USD","LU0128525929.USD","LU2237443549.SGD","LU2237443622.USD","LU2456880835.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664568448","title":"Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2664568448","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664568448?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:49","pubTimestamp":1788263354,"startTime":"0","endTime":"0","summary":"FACTBOX-Global pharma companies that have publicly announced Trump drug pricing agreementsSept 1 (Reuters)-U.S. President Donald Trump has struck drug-pricing deals with more than 20 pharmaceutical co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nL4N44T0TS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2028103732.USD","BIB","LU0943347566.SGD","LU0949170772.SGD","IE00B1XK9C88.USD","SG9999001440.SGD","LU0738911758.USD","LU2242646821.SGD","LU1585245621.USD","LU0868494617.USD","LU1043141123.HKD","LU1868837300.USD","LU0267386448.USD","SG9999015358.SGD","LU0211328371.USD","LU1366192091.USD","LU0058720904.USD","LU1868836591.USD","LU2087625088.SGD","LU0648001328.SGD","LU0306807586.USD","LU1066051498.USD","LU2213496289.HKD","LU2347655073.USD","SG9999018857.SGD","LU1623119135.USD","VHT","AMGN","SG9999002232.USD","LU0256863811.USD","LU1720051108.HKD","IE000MB6IJN5.SGD","IE0009355771.USD","LU0385154629.USD","LU1934455277.USD","CANC","GDOC","LU0889565916.HKD","LU2089283258.USD","LU2168563687.JPY","LU1116320737.USD","LU1035773651.USD","LU1496350502.SGD","LU2491049909.HKD","04332","IE00BVYPNV92.GBP","LU2357305700.SGD","LU2491050071.SGD","LU0395794307.EUR","LU1221951046.USD","06160","LU1145028129.USD","LU1935042991.SGD","LU0306806265.USD","PBE","LU1221951129.SGD","LU0130102774.USD","BK4559","LU0203345920.USD","LU1670711040.USD","LU0689626769.HKD","LU1064131342.USD","MEDX","BK7501","LU2462157665.USD","IE00BGHQF631.EUR","LU2237443622.USD","LU2746668974.SGD","IE0002141913.USD","LU0426412945.USD","LU0345770993.USD","LU1674673428.USD","LU0545039389.USD","LU0234570918.USD","LU0320765646.SGD","LU0985481810.HKD","LU0882574139.USD","BK4532","LU1236620834.HKD","LU1267930730.SGD","LU1670710661.SGD","LU0203202063.USD","SG9999015945.SGD","LU0158827781.USD","LU0289739699.SGD","LU1267930573.SGD","BK4578","GSK.UK","IE00BZ1G4Q59.USD","LU0466842654.USD","LU2505996681.GBP","IE00BKDWB100.SGD","LU0354030511.USD","LU2125154778.USD","LU2750360997.AUD","BK4534","PAWZ","LU2430703251.USD","SGXZ31699556.SGD","SG9999014575.USD","CSL.AU","LU0511384066.AUD","LU0708995401.HKD","IE00BFSS7M15.SGD","LU1066053197.SGD","LU0109391861.USD","BK4007","LU0861579265.USD","LU0985320562.USD","LU1691799644.USD","LU0786609619.USD","MEDI","ILDR","SG9999001176.SGD","LU0133085943.USD","LU0128525929.USD","IE00BN29S564.USD","SG9999015986.USD","LU2168564149.EUR","LU0965508806.USD","IE00BK4W5M84.HKD","LU1551013342.USD","LU2471134796.USD","IE00BK4W5L77.USD","LU1868836914.USD","LU2023250843.SGD","IE000BZT7R73.USD","LU0320765059.SGD","LU2087621335.USD","LU1974910355.USD","LU1699723380.USD","IE00BDGV0183.EUR","LU0964807845.USD","LU2237443465.HKD","FHLC","SG9999001176.USD","LU2264538146.SGD","LU2125909247.SGD","SG9999014542.SGD","LU1934455863.HKD","LU1934455194.USD","LU2362541273.HKD","IE00B2B36J28.USD","LU2023250330.USD","LU1548497426.USD","SG9999014559.SGD","BK4585","LU0820562030.AUD","LU1201861249.SGD","MHIP","TRUH","IE00BJT1NW94.SGD","LU2023250504.SGD","BK4139","NVO","LU1035775433.USD","LU2361044949.HKD","IE000M9KFDE8.USD","LU2360032135.SGD","BK4568","BBIO","LU1571399168.USD","LU1323610961.USD","LU2487616109.SGD","LU1839511570.USD","LU1093756325.SGD","LU1894683264.USD","IE00BKPKM429.USD","LU0820561818.USD","LU1989771016.USD","LU2896262040.SGD","LU0345769631.USD","IHE","GILD","LU1037948897.HKD","LU0210528500.USD","LU1121112475.USD","LU0238689110.USD","LU1929549753.HKD","LU2361045086.USD","LU0795875169.SGD","IE00BFSS8Q28.SGD","LU0170899867.USD","LU0820561909.HKD","SGXZ80539844.SGD","SG9999018865.SGD","LU0174119429.USD","IE00BJJMRX11.SGD","LU2417539215.USD","BMED","LU0211327993.USD","LU2456880835.USD","LU2168564065.EUR","NVOH","LU0889566641.SGD","AZNH","JDOC","SGXZ81514606.USD","LU1551013425.SGD","LU0154236417.USD","LU2596442595.SGD","LU2552382215.SGD","LU2602419157.SGD","LU1037948541.HKD","LU2491050154.USD","LU0942090050.USD","LU1061106388.HKD","IE00BFTCPJ56.SGD","IE00B7SZLL34.SGD","LU2236285917.USD","LU0203201768.USD","BMY","LU0072461881.USD","LU1670628061.USD","IE000WAW04H5.SGD","LU0471298777.SGD","LU2237443978.SGD","LU2471134952.CNY","LU1732800096.USD","LU1291159041.SGD","LU1059921491.USD","LU1804176565.USD","LU1280957306.USD","LU2461242641.AUD","LU0070217475.USD","BK4588","LU0726765562.USD","LU2433249047.HKD","IE0002270589.USD","GLAM","LU0859254822.USD","LU2111349929.HKD","LU0683600562.USD","SG9999013999.USD","LU1989772923.USD","LU1979441026.SGD","LU1066051225.USD","LU2361044865.SGD","LU1941712264.USD","LU1023059063.AUD","LU1868837136.USD","LU1506573853.SGD","LU2430703178.SGD","LU2129689431.USD","LU0069063385.USD","IE00BJLML261.HKD","HRTS","LU0882574055.USD","LU2168564222.USD","LU0098860793.USD","LU0053666078.USD","LU0965509283.SGD","LU0965509101.SGD","LU0094547139.USD","LU1629891620.HKD","LLY","RXL","LU1267930813.SGD","IE000SO60NU8.SGD","LU0061475181.USD","ABBV","BK4504","LU0321505439.SGD","LU2125909593.SGD","BK7508","LU2237443382.USD","LU0353189763.USD","ONC","LU0070302665.USD","LU0323591593.USD","IE0001KFT4U8.USD","SG9999014898.SGD","LU1917777945.USD","LU0316494557.USD","LU0353189680.USD","LU0426417589.USD","IE00B775H168.HKD","IE00BKVL7J92.USD","LU1732799900.SGD","LU0792757196.USD","LU0158827948.USD","LU0211331839.USD","LU0130517989.USD","LU2362541513.USD","IE0004445239.USD","LLYZ","LU1674673691.USD","LU0256863902.USD","SGXZ99366536.SGD","BK4516","BK4505","LU2552382132.HKD","LU1196500208.SGD","LU0225283273.USD","688235","PPH","LU1718418525.SGD","AGNG","IE00B19Z3581.USD","LU2468319806.SGD","LU2471134523.USD","LU2746668461.USD","LU0310800379.SGD","SG9999003800.SGD","LU1116320901.HKD","NVOX","SG9999017495.SGD","LU2750360641.GBP","SG9999014567.USD","IE00BJJMRY28.SGD","TBXU","LU0266013472.USD","PFE","LU2347655156.SGD","IXJ","LU0198837287.USD","LU1244550577.SGD","IE00B3PB1722.GBP","LU2063271972.USD","LU2168564495.EUR","LU1778281490.HKD","LU2242652126.USD","LU1244550221.USD","BK7067","LU0553294199.USD","AZN","GSKH","LU0208291251.USD","LU2265009873.SGD","LU2237438978.USD","SG9999014906.USD","LU2430703095.HKD","BK4583","SG9999015952.SGD","LU1923622614.USD","IE00BSNM7G36.USD","BK4592","IE00BVYPNW00.USD","IE00B3T34201.USD","LU0162691827.USD","LU1236620750.USD","SGXZ57979304.SGD","LU1032466523.USD","IBB","LU0265550946.USD","LU0265550359.USD","LU0237698245.USD","LU1003077747.HKD","LU0994945656.USD","IE00BJJMRZ35.SGD","LU2756315664.SGD","ELIL","JNJ","BK4533","MRK","SG9999014914.USD","LU1989772840.SGD","LU0006306889.USD","LU2362540622.SGD","LU1914381329.SGD","LU2592432038.USD","LU2089284900.SGD","LU2357627491.SGD","LU0109394709.USD","BK4599","GB00BDT5M118.USD","LU0545562505.USD","LU0225771236.USD","BK7511","LU2360106947.USD","BK4581","LU1162221912.USD","LU2271345857.HKD","IE00B4R5TH58.HKD","ELIS","LU0203347892.USD","LU0912757837.SGD","IE00B7KXQ091.USD","GSK","LU0472753341.HKD","LU2089984988.USD","XLV","LU1883839398.USD","IE0000B7K699.USD","BK0239","NVS","LU0640476718.USD","LU1829250122.USD","LU1430594728.SGD","LU0210536198.USD","LU1712237335.SGD","LU0354030438.USD","LU1074936037.SGD","LU2106854487.HKD","LU0345770308.USD","BBH","LU1127390331.HKD","LU0477156953.USD","LU1043141396.HKD","CURE","REGN","IE00B1BXHZ80.USD","LU0456855351.SGD","SG9999002224.SGD","LU0289739343.SGD","IE00B42XCP33.USD","LU1496350171.SGD","IE00B4JS1V06.HKD","LU2211815571.USD","LU1228905540.USD","LU0321505868.SGD","SG9999015978.USD","LU1093756168.USD","LU0471298694.HKD","LU1069347547.HKD","LU0980610538.SGD","LU2505996509.AUD","LU0823434583.USD","LU0320765489.SGD","LU2552382058.USD","WDNA","LU1983299246.USD","THNR","LU0097036916.USD","LU0096364046.USD","LU2129689605.HKD","LU1261432733.SGD","BK4550","SG9999014880.SGD","LU2237443895.HKD","LU2471134879.HKD","IE0034235303.USD","NVOC","LU1670710588.SGD","LU0114720955.EUR","LU1988902786.USD","LLII","LU0029864427.USD","IYH","LU2108987350.USD","LU1814569148.SGD","LU0345769128.USD","LU1244550494.USD","LU0320765992.SGD","LU0708994859.HKD","LU1267930490.SGD","LU1228905037.USD","IE00BN8TJ469.HKD","LU1066051811.HKD","LU2129689514.USD","LU0823416689.USD","IE00BWXC8680.SGD","LU2023251221.USD","LU1232071149.USD","LU0661504455.SGD","LU0417517546.SGD","IE00BLSP4239.USD","IE0004445015.USD","LU0672654240.SGD","LU1670627923.USD","LU1941712348.USD","LU1894683348.USD","LU2133065610.SGD","IE0005OL40V9.USD","IE00B19Z3B42.SGD","LU0057025933.USD","LU2125154935.USD","LU0122379950.USD","LU0795875086.SGD","LU0310799852.SGD","LU1069344957.HKD","PJP","LU2756315318.SGD","LU2112291526.USD","LU1720051017.SGD","IE00BLSP4452.SGD","LU1670711123.USD","IE000F7OJYX1.SGD","IE00BBT3K403.USD","LU0868494708.USD","LU2237443549.SGD","LU1032955483.USD","LU0689472784.USD","LU2324357040.USD","SGXZ51526630.SGD","FTXH","BK4566","LU1868836757.USD","LU0106261372.USD","LU0124676726.USD","LU0432979614.USD","LU0289961442.SGD","LU0965509010.AUD","TMED","LU2462591350.SGD","LU0079474960.USD","LU0787776722.HKD","OZEM","SG9999011175.SGD","LU2403377893.USD","LU0234572021.USD","LU0823434740.USD","LU1057294990.SGD","LU0225284248.USD","LLYX","IE00BFXG1179.USD","SG9999015341.SGD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664555058","title":"AstraZeneca completes global license agreement for Zegfrovy in lung cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664555058","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664555058?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:10","pubTimestamp":1788261040,"startTime":"0","endTime":"0","summary":"AstraZeneca (AZN) announced the completion of the exclusive license agreement with Dizal Pharmaceutical for Zegfrovy – sunvozertinib -, an oral irr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astrazeneca-completes-global-license-agreement-for-zegfrovy-in-lung-cancer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astrazeneca-completes-global-license-agreement-for-zegfrovy-in-lung-cancer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","LU2089984988.USD","BK4007","AZNH","LU0310800379.SGD","LU2468319806.SGD","LU2237443549.SGD","LU2456880835.USD","LU0289739699.SGD","LU0320765992.SGD","LU2462157665.USD","LU0058720904.USD","BK4568","LU0432979614.USD","BK4585","LU2237443622.USD","LU1829250122.USD","LU2237443895.HKD","LU2237443978.SGD","AZN","LU2236285917.USD","LU0128525929.USD","IE00B3T34201.USD","LU0889565916.HKD","LU2417539215.USD","BK4588","LU1267930573.SGD","LU0029864427.USD","LU0708994859.HKD","LU2237443382.USD","LU2237443465.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664322228","title":"AstraZeneca Reports 'Meaningful Improvement' in Phase 3 Study of Lung Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2664322228","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664322228?lang=en_us&edition=fundamental","pubTime":"2026-09-01 17:01","pubTimestamp":1788253304,"startTime":"0","endTime":"0","summary":"AstraZeneca  said early Tuesday that Tagrisso plus Orpathys in a phase 3 trial showed a \"statistically significant and highly clinically meaningful improvement\" in progression-free survival versus tagrisso alone in a trial of newly diagnosed lung cancer patients.The SANOVO Phase 3 trial included 326 patients in China who had not previously been treated for advanced lung cancer with specific genetic changes, according to AstraZeneca.The benefit was seen in both the high MET and intention-to-treat trial populations, the company said. The combination also showed what the company described as very encouraging clinical benefit in overall survival, which is a secondary endpoint, although the trial will continue to follow patients.The safety profile for Tagrisso plus Orpathys was consistent with the known profiles of each medicine, and no new safety findings emerged.The results from the trial reinforce tagrisso as the backbone therapy across epidermal growth factor receptor-mutated lung cance","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4568","LU0289739699.SGD","IE00B3T34201.USD","LU2237443622.USD","LU0029864427.USD","LU2456880835.USD","AZN","LU0320765992.SGD","BK4007","LU2237443895.HKD","LU2237443978.SGD","LU0432979614.USD","LU2089984988.USD","BK4585","AZNH","LU2237443465.HKD","LU2237443382.USD","BK4588","LU0889565916.HKD","LU0128525929.USD","LU0109394709.USD","LU2468319806.SGD","LU1267930573.SGD","LU2236285917.USD","LU0058720904.USD","LU0708994859.HKD","LU2237443549.SGD","LU2417539215.USD","LU0310800379.SGD","LU2462157665.USD","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664739831","title":"AstraZeneca Says Breast Cancer Combo Approved in EU; Completes Acquisition of License for Lung Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2664739831","media":"MT Newswires Live","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664739831?lang=en_us&edition=fundamental","pubTime":"2026-09-01 15:58","pubTimestamp":1788249536,"startTime":"0","endTime":"0","summary":"AstraZeneca  and Daiichi Sankyo's combination of Enhertu plus pertuzumab has been approved in the European Union as a first-line treatment of patients with HER2-positive metastatic breast cancer, the companies said Tuesday.The approval triggers a $100 million milestone payment by AstraZeneca to Daiichi Sankyo. It was based on a phase 3 study that showed the drug combination reduced the risk of disease progression or death by 44% compared with the standard of care.Astrazeneca also said it has completed its previously announced worldwide exclusive license agreement with Dizal Pharamceutical for Zegfrovy, a treatment for patients with lung cancer.The company will make an upfront payment of $600 million to Dizal, along with additional payments of up to $900 million on achievement of specific development.Under the deal, Dizal will also receive royalties on sales of Zegfrovy, the company said.The payout does not impact AstraZeneca's 2026 financial guidance, it added.AstraZeneca shares were d","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0708994859.HKD","LU2089984988.USD","LU2468319806.SGD","BK4568","LU2237443978.SGD","LU2236285917.USD","LU0289739699.SGD","LU0128525929.USD","IE00B3T34201.USD","LU0109394709.USD","LU1267930573.SGD","LU2237443895.HKD","BK4585","LU2237443382.USD","BK4588","LU2456880835.USD","LU2237443622.USD","LU2237443549.SGD","LU0432979614.USD","LU0310800379.SGD","AZNH","AZN","LU0058720904.USD","LU2237443465.HKD","LU0889565916.HKD","LU2417539215.USD","LU0320765992.SGD","BK4007","LU2462157665.USD","LU1829250122.USD","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664002661","title":"AstraZeneca PLC Stock Rises Monday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2664002661","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664002661?lang=en_us&edition=fundamental","pubTime":"2026-09-01 00:00","pubTimestamp":1788192000,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of AstraZeneca PLC advanced 0.3% to SEK1,563.50 Monday on what proved to be an overall negative trading session for the stock market, with the OMX Nordic 40 Index falling 0.9% to 2,707.24.The stock's rise  snapped a three-day losing streak.The company closed SEK362.00 below its 52-week high of SEK1,925.50, which the company reached on April 10, 2026.Trading volume was 352,573, compared to the 50-day average trading volume of 546,664.Data source: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0432979614.USD","LU2417539215.USD","LU0320765992.SGD","LU1829250122.USD","LU2456880835.USD","LU0289739699.SGD","LU0058720904.USD","LU2237443895.HKD","LU2468319806.SGD","AZN","LU2237443978.SGD","LU0310800379.SGD","LU0029864427.USD","AZNH","BK4568","LU2237443549.SGD","LU0109394709.USD","LU0889565916.HKD","LU1267930573.SGD","LU2237443622.USD","LU0128525929.USD","LU2462157665.USD","LU2089984988.USD","IE00B3T34201.USD","BK4585","BK4007","LU2236285917.USD","LU2237443382.USD","LU0708994859.HKD","BK4588","LU2237443465.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663781170","title":"Hutchmed Says Lung Cancer Therapy Improves Progression-Free Survival in China Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2663781170","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663781170?lang=en_us&edition=fundamental","pubTime":"2026-08-31 15:38","pubTimestamp":1788161936,"startTime":"0","endTime":"0","summary":"Hutchmed  said Monday its experimental combination of Orpathys and Tagrisso demonstrated a statistically significant improvement in progression-free survival in a China phase 3 trial involving certain patients with non-small cell lung cancer.The company said the combination also showed encouraging overall survival benefits compared with Tagrisso alone, which was a secondary endpoint of the trial.Orpathys is jointly developed by AstraZeneca  and Hutchmed and commercialized by AstraZeneca, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1267930573.SGD","BK4007","BK4531","LU0128525929.USD","LU0432979614.USD","LU2237443549.SGD","LU2089984988.USD","LU2237443895.HKD","BK4588","IE00B3T34201.USD","LU0029864427.USD","LU0320765992.SGD","AZN","LU0289739699.SGD","AZNH","LU2237443622.USD","LU0708994859.HKD","LU2236285917.USD","LU2237443465.HKD","LU1829250122.USD","LU2237443978.SGD","LU0058720904.USD","BK4568","LU2417539215.USD","LU0889565916.HKD","LU0109394709.USD","LU0310800379.SGD","LU2468319806.SGD","LU2462157665.USD","HCM","LU2456880835.USD","BK4585","LU2237443382.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663920590","title":"AstraZeneca PLC Stock Falls Friday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2663920590","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663920590?lang=en_us&edition=fundamental","pubTime":"2026-08-29 00:00","pubTimestamp":1787932800,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of AstraZeneca PLC shed 0.8% to SEK1,559.00 Friday on what proved to be an overall favorable trading session for the stock market, with the OMX Nordic 40 Index rising 0.1% to 2,733.09.This was the stock's third consecutive day of losses.The company closed SEK366.50 short of its 52-week high of SEK1,925.50, which the company achieved on April 10, 2026.Trading volume was 377,982, compared to the 50-day average trading volume of 543,948.Data source: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0310800379.SGD","LU0109394709.USD","BK4588","LU2468319806.SGD","LU0432979614.USD","LU2456880835.USD","LU2237443465.HKD","BK4007","LU1829250122.USD","BK4568","LU1267930573.SGD","LU0128525929.USD","BK4585","LU0889565916.HKD","LU2237443382.USD","LU0289739699.SGD","AZNH","LU0058720904.USD","LU2462157665.USD","LU0029864427.USD","LU2236285917.USD","LU2237443978.SGD","LU0320765992.SGD","LU2237443549.SGD","LU2237443895.HKD","LU0708994859.HKD","LU2237443622.USD","LU2417539215.USD","LU2089984988.USD","IE00B3T34201.USD","AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662093221","title":"Jefferies sees neutral to negative read-through to Alnylam from AstraZeneca data","url":"https://stock-news.laohu8.com/highlight/detail?id=2662093221","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662093221?lang=en_us&edition=fundamental","pubTime":"2026-08-28 20:50","pubTimestamp":1787921420,"startTime":"0","endTime":"0","summary":"After Ionis Pharmaceuticals (IONS) and AstraZeneca (AZN) presented full results of the Cardio-TTRansform trial at the ESC Congress 2026 in Munich, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jefferies-sees-neutral-to-negative-read-through-to-alnylam-from-astrazeneca-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jefferies-sees-neutral-to-negative-read-through-to-alnylam-from-astrazeneca-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","LU0289739699.SGD","IE00B3T34201.USD","LU2237443622.USD","LU0029864427.USD","LU2456880835.USD","BK4139","AZN","LU0320765992.SGD","BK4007","LU2237443895.HKD","LU2237443978.SGD","LU0432979614.USD","LU2089984988.USD","BK4585","AZNH","LU2237443465.HKD","LU2237443382.USD","BK4588","LU0889565916.HKD","LU0128525929.USD","LU0109394709.USD","LU2468319806.SGD","IONS","LU1267930573.SGD","LU2236285917.USD","LU0058720904.USD","LU0708994859.HKD","LU2237443549.SGD","LU2417539215.USD","LU0310800379.SGD","LU2462157665.USD","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662084908","title":"AstraZeneca Targets Pediatric Asthma Gains With New Glycopyrronium Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2662084908","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662084908?lang=en_us&edition=fundamental","pubTime":"2026-08-28 00:31","pubTimestamp":1787848302,"startTime":"0","endTime":"0","summary":"AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca plc (AZN) is running a Phase II trial called “A Phase II...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/astrazeneca-targets-pediatric-asthma-gains-with-new-glycopyrronium-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/astrazeneca-targets-pediatric-asthma-gains-with-new-glycopyrronium-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LU2237443382.USD","LU2468319806.SGD","LU2462157665.USD","LU0289739699.SGD","LU1267930573.SGD","LU0058720904.USD","LU0320765992.SGD","LU0029864427.USD","LU2089984988.USD","LU0310800379.SGD","BK4588","LU2236285917.USD","LU0128525929.USD","AZNH","LU2237443895.HKD","IE00B3T34201.USD","LU2237443978.SGD","LU0432979614.USD","LU2237443549.SGD","LU2237443622.USD","LU1829250122.USD","LU0889565916.HKD","LU2417539215.USD","LU2456880835.USD","LU2237443465.HKD","BK4568","BK4585","LU0708994859.HKD","LU0109394709.USD","AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662995084","title":"AstraZeneca Advances Off‑the‑Shelf CAR‑T Program in Tough‑to‑Treat Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2662995084","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662995084?lang=en_us&edition=fundamental","pubTime":"2026-08-28 00:31","pubTimestamp":1787848284,"startTime":"0","endTime":"0","summary":"AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca (AZN) is advancing a new study of AZD4045 in adults with...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/astrazeneca-advances-offtheshelf-cart-program-in-toughtotreat-multiple-myeloma?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/astrazeneca-advances-offtheshelf-cart-program-in-toughtotreat-multiple-myeloma?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AZNH","LU1267930573.SGD","LU2237443622.USD","LU2236285917.USD","LU0432979614.USD","BK4568","BK4007","LU2237443549.SGD","LU0310800379.SGD","AZN","LU2237443382.USD","LU2237443465.HKD","LU0289739699.SGD","LU0128525929.USD","LU1829250122.USD","LU0029864427.USD","IE00B3T34201.USD","LU2237443978.SGD","LU0058720904.USD","LU0708994859.HKD","LU2456880835.USD","BK4588","LU2468319806.SGD","LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","LU2462157665.USD","LU2089984988.USD","LU2417539215.USD","BK4585","LU2237443895.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662013447","title":"Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements","url":"https://stock-news.laohu8.com/highlight/detail?id=2662013447","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662013447?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:15","pubTimestamp":1787829352,"startTime":"0","endTime":"0","summary":"Positive high-level results from the Phase III CROSSING trial in patients with eosinophilic esophagitis showed that AstraZeneca (AZN) and Amgen’s (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-announce-crossing-trial-showed-meaningful-improvements-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-announce-crossing-trial-showed-meaningful-improvements-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1267930573.SGD","LU0432979614.USD","BIB","LU0708994859.HKD","BK4533","BK4568","IE00B4R5TH58.HKD","BK4581","LU2237443978.SGD","AZN","LU2089984988.USD","BK4585","BK4588","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU2417539215.USD","IE0002141913.USD","LU0289739699.SGD","LU2242646821.SGD","LU1829250122.USD","IBB","PJP","LU2237443465.HKD","LU1057294990.SGD","LU2237443382.USD","LU0029864427.USD","BK4139","IE0009355771.USD","LU2237443622.USD","TBXU","IE00BFTCPJ56.SGD","LU0128525929.USD","AMGN","LU1023059063.AUD","AZNH","LU2456880835.USD","BK4007","LU0868494617.USD","BBH","LU2236285917.USD","IE00BJJMRZ35.SGD","PBE","BK4534","IBBQ","LU2242652126.USD","LU0122379950.USD","LU2462157665.USD","LU2468319806.SGD","BK4566","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662877754","title":"Amgen, AstraZeneca report CROSSING trial met co-primary and secondary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2662877754","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662877754?lang=en_us&edition=fundamental","pubTime":"2026-08-27 17:15","pubTimestamp":1787822113,"startTime":"0","endTime":"0","summary":"Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 CROSSING trial of Tezspire in patients living with eosinophilic esop...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-report-crossing-trial-met-co-primary-and-secondary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-report-crossing-trial-met-co-primary-and-secondary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0432979614.USD","BK4581","BK4566","LU1061106388.HKD","BK4533","IE00B2B36J28.USD","LU2112291526.USD","LU1023059063.AUD","LU2237443978.SGD","BIB","BK4585","IBBQ","AZN","LU0128525929.USD","LU2242646821.SGD","PBE","LU2237443465.HKD","LU2456880835.USD","LU2236285917.USD","LU0058720904.USD","BK4007","IE00B3T34201.USD","BK4568","IE0009355771.USD","IBB","LU0889565916.HKD","LU1983299246.USD","BBH","LU0029864427.USD","LU0122379950.USD","LU1829250122.USD","LU1267930573.SGD","LU1571399168.USD","IE0002141913.USD","LU2468319806.SGD","PJP","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU2237443895.HKD","BK4588","BK4599","LU0868494617.USD","LU2417539215.USD","TBXU","AZNH","IE00BJJMRZ35.SGD","AMGN","LU1057294990.SGD","LU0320765992.SGD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662771175","title":"AstraZeneca, Amgen Phase 3 Trial Shows Tezspire Eases Swallowing Difficulties for EoE Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2662771175","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662771175?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:24","pubTimestamp":1787819085,"startTime":"0","endTime":"0","summary":"AstraZeneca  and Amgen  said Thursday their drug Tezspire met the primary endpoints of a Phase 3 trial treating eosinophilic esophagitis, a chronic inflammatory esophagus disorder.The medication met both primary endpoints by reducing tissue inflammation and easing swallowing difficulties at week 24 compared to a placebo, the companies said.The disease and symptom improvements were maintained through week 52 for both tested doses, they said.The companies also said the safety profile of the treatment during the study remained consistent with its previously approved uses.Shares of Amgen were down by over 1% in Thursday premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4599","IBBQ","IE00BFTCPJ56.SGD","LU2237443549.SGD","LU2237443622.USD","BK4581","AZNH","LU1057294990.SGD","LU2237443465.HKD","PJP","LU2112291526.USD","BK4007","BK4533","LU0109394709.USD","AZN","LU1983299246.USD","LU2456880835.USD","LU0128525929.USD","IBB","BIB","LU0889565916.HKD","LU2242646821.SGD","LU2237443895.HKD","TBXU","AMGN","LU0289739699.SGD","LU0310800379.SGD","LU1061106388.HKD","LU0868494617.USD","LU2242652126.USD","LU0029864427.USD","BK4585","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0708994859.HKD","LU2089984988.USD","BK4534","LU1829250122.USD","PBE","BBH","BK4566","LU0432979614.USD","LU2237443382.USD","LU1571399168.USD","LU2237443978.SGD","LU2462157665.USD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","LU1267930573.SGD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662101775","title":"AstraZeneca's Tezspire Meets Esophagitis Late-Stage Trial Goals","url":"https://stock-news.laohu8.com/highlight/detail?id=2662101775","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662101775?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:52","pubTimestamp":1787813520,"startTime":"0","endTime":"0","summary":"AstraZeneca reported positive results from its Phase 3 trial of Tezspire in patients with eosinophilic esophagitis, an inflammatory disorder of the esophagus.The Cambridge-based pharmaceutical company said Thursday that the drug demonstrated improvements across co-primary and all key secondary endpoints at week 24 of the trial, which were sustained to week 52.The co-primary endpoints were histologic remission and the frequency and severity of dysphagia--or difficulty swallowing--compared with the placebo. The safety profile of the drug was generally consistent with its approved indications, AstraZeneca added.The drug is being developed in collaboration with U.S. biotechnology company Amgen.Tezspire is currently approved for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps in the U.S., EU, China and Japan.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443465.HKD","LU0109394709.USD","AZNH","LU2236285917.USD","LU0310800379.SGD","LU2468319806.SGD","LU2237443978.SGD","LU2237443382.USD","IE00B3T34201.USD","BK4007","LU0128525929.USD","LU2237443895.HKD","BK4588","LU2089984988.USD","LU2462157665.USD","LU0058720904.USD","LU0432979614.USD","LU2237443622.USD","LU0708994859.HKD","AZN","BK4585","LU2456880835.USD","LU1267930573.SGD","LU0029864427.USD","BK4568","LU0889565916.HKD","LU0320765992.SGD","LU2237443549.SGD","LU2417539215.USD","LU0289739699.SGD","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662745884","title":"AstraZeneca Slides Wednesday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2662745884","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662745884?lang=en_us&edition=fundamental","pubTime":"2026-08-27 00:06","pubTimestamp":1787760360,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of AstraZeneca PLC  slid 1.94% to GBP122.34 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index  falling 0.07% to 10,878.12.AstraZeneca PLC closed 22.23% short of its 52-week high of GBP157.32, which the company reached on February 18th.Trading volume totaled 2.0 million, compared to the 50-day average of 3.3 million.Data source: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZNH","LU1267930573.SGD","LU2237443622.USD","LU2236285917.USD","LU0432979614.USD","BK4568","BK4007","LU2237443549.SGD","LU0310800379.SGD","AZN","LU2237443382.USD","LU2237443465.HKD","LU0289739699.SGD","LU0128525929.USD","LU1829250122.USD","LU0029864427.USD","IE00B3T34201.USD","LU2237443978.SGD","LU0058720904.USD","LU0708994859.HKD","LU2456880835.USD","BK4588","LU2468319806.SGD","LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","LU2462157665.USD","LU2089984988.USD","LU2417539215.USD","BK4585","LU2237443895.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662759855","title":"AstraZeneca Deepens Its Type 2 Diabetes Pipeline With New Global Patient Mapping Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2662759855","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662759855?lang=en_us&edition=fundamental","pubTime":"2026-08-26 00:30","pubTimestamp":1787675440,"startTime":"0","endTime":"0","summary":"AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca plc (AZN) is running an observational study titled “A St...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/astrazeneca-deepens-its-type-2-diabetes-pipeline-with-new-global-patient-mapping-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/astrazeneca-deepens-its-type-2-diabetes-pipeline-with-new-global-patient-mapping-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029864427.USD","LU2417539215.USD","LU2237443622.USD","LU2089984988.USD","LU2237443978.SGD","LU1829250122.USD","AZN","LU0320765992.SGD","LU2456880835.USD","BK4568","LU0310800379.SGD","LU0889565916.HKD","LU0432979614.USD","LU2237443895.HKD","LU0109394709.USD","LU2236285917.USD","LU2468319806.SGD","IE00B3T34201.USD","LU1267930573.SGD","LU2237443465.HKD","AZNH","LU2237443549.SGD","LU0708994859.HKD","BK4585","LU0058720904.USD","LU2237443382.USD","LU0128525929.USD","BK4007","BK4588","LU2462157665.USD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662756389","title":"AstraZeneca Climbs Tuesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2662756389","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662756389?lang=en_us&edition=fundamental","pubTime":"2026-08-26 00:05","pubTimestamp":1787673900,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of AstraZeneca PLC  rallied 3.02% to GBP124.76 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index  rising 0.29% to 10,886.16.AstraZeneca PLC closed 20.70% short of its 52-week high of GBP157.32, which the company achieved on February 18th.Trading volume totaled 1.4 million, compared to the 50-day average of 3.3 million.Data source: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","LU0432979614.USD","IE00B3T34201.USD","LU1829250122.USD","LU2236285917.USD","LU0109394709.USD","LU2468319806.SGD","LU0708994859.HKD","AZNH","LU0058720904.USD","LU1267930573.SGD","BK4588","LU2462157665.USD","LU2237443549.SGD","LU2237443622.USD","LU2237443895.HKD","LU0889565916.HKD","LU0029864427.USD","LU2237443978.SGD","LU0310800379.SGD","LU2237443382.USD","LU0320765992.SGD","LU0128525929.USD","LU2237443465.HKD","LU2456880835.USD","AZN","BK4007","LU0289739699.SGD","BK4585","BK4568","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662835787","title":"AstraZeneca (AZN) Receives a Sell from Deutsche Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2662835787","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662835787?lang=en_us&edition=fundamental","pubTime":"2026-08-25 16:36","pubTimestamp":1787646972,"startTime":"0","endTime":"0","summary":"In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on AstraZeneca, with a price target of £115.00. Papadaki...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/astrazeneca-azn-receives-a-sell-from-deutsche-bank-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/astrazeneca-azn-receives-a-sell-from-deutsche-bank-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0058720904.USD","IE00B3T34201.USD","BK4568","LU2089984988.USD","LU0432979614.USD","LU2417539215.USD","LU2462157665.USD","LU0889565916.HKD","LU0109394709.USD","AZN","LU2468319806.SGD","LU2237443622.USD","BK4007","LU0029864427.USD","LU0289739699.SGD","LU2237443549.SGD","LU0708994859.HKD","LU1829250122.USD","DB","BK4585","LU1267930573.SGD","LU0310800379.SGD","LU2237443382.USD","LU0128525929.USD","BK4118","BK4588","LU2237443465.HKD","LU2456880835.USD","LU0320765992.SGD","LU2237443978.SGD","BK4552","AZNH","LU2237443895.HKD","BK4566","LU2236285917.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662378470","title":"Astrazeneca Prices $2.97 Billion Eurobond Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2662378470","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662378470?lang=en_us&edition=fundamental","pubTime":"2026-08-25 16:12","pubTimestamp":1787645532,"startTime":"0","endTime":"0","summary":"Astrazeneca  has priced four tranches of Eurobonds totalling 2.55 billion euros , the company said Tuesday.The offering is expected to close on Sept. 1.The offering consisted of 700 million euros of fixed-rate notes with a coupon of 3.402% maturing in 2030; 600 million euros of fixed-rate notes with a coupon of 3.652% maturing in 2032; 500 million euros of fixed-rate notes with a coupon of 3.923% maturing in 2035; and750 million euros of fixed-rate notes with a coupon of 4.169% maturing in 2038, the company said.The company plans to use the net proceeds of the offering for general corporate purposes, it said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2237443549.SGD","AZN","LU2462157665.USD","LU0889565916.HKD","BK4585","LU0289739699.SGD","LU2089984988.USD","LU0128525929.USD","LU2236285917.USD","LU0109394709.USD","LU2237443895.HKD","BK4568","LU0320765992.SGD","LU2237443382.USD","BK4007","BK4588","LU2456880835.USD","IE00B3T34201.USD","LU1267930573.SGD","LU2468319806.SGD","LU0029864427.USD","LU1829250122.USD","LU2237443978.SGD","LU2417539215.USD","LU0432979614.USD","LU0058720904.USD","LU2237443465.HKD","LU0708994859.HKD","LU2237443622.USD","LU0310800379.SGD","AZNH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}